ACAD vs CUBE · P/E 15, rev $957.8M vs P/E 25, rev $1.07B
ACADIA Pharmaceuticals Inc (ACAD) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported ACAD revenue for 2024-12-31 was $957.8M. Net income was $226.5M. Revenue was up 314.6% from 2023-12-31 to 2024-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the ACAD and CUBE stock pages for the full models.
Not investment advice.